Evidence map›Paper›PMID 37742019›Full record

Trial reportStem cell research & therapy2023

Efficacy of fractional CO

Masoumeh Roohaninasab, Fariba Khodadad, Afsaneh Sadeghzadeh-Bazargan, Najmolsadat Atefi, Sona Zare, Alireza Jafarzadeh, Seyyedeh Tahereh Rahimi, Maryam Nouri, Mohammad Ali Nilforoushzadeh, Elham Behrangi and 1 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Stem cell research & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 8 pooled it
10.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 8 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Masoumeh RoohaninasabDepartment of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Fariba KhodadadDepartment of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Afsaneh Sadeghzadeh-BazarganDepartment of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Najmolsadat AtefiDepartment of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Sona ZareSkin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Alireza JafarzadehDepartment of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Seyyedeh Tahereh RahimiDepartment of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Maryam NouriSkin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad Ali NilforoushzadehSkin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran. M.a.nilforoushzadeh2022@gmail.com.ORCID http://orcid.org/0000-0001-6143-8039
Elham BehrangiDepartment of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran. behrangi.e@iums.ac.ir.ORCID http://orcid.org/0000-0002-6545-3460
Azadeh GoodarziDepartment of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Iran University of Medical Sciences · IRNational Iranian Oil Company (Iran) · IRSharif University of Technology · IRTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe appearance of skin scars is known as one of the main side effects of skin burns. Stromal vascular fraction (SVF), as a rich source of cell populations with tissue regeneration properties, plays an important role in the healing of skin lesions. Fractional CO

methodThis double-blind clinical trial study was conducted on ten patients with burn scars that were treated three times with a fractional CO

resultsThe results confirmed a significant improvement in VSS, cutometry, R7 criteria, complete density sonography, and skin density sonography in the fractional CO

conclusionThe results confirm the efficacy of SVF injection in combination with fractional CO

trial registrationThe study protocol was retrospectively registered at Iranian Registry of Clinical Trials with code: IRCT20210515051307N1, Registration date: 2021-11-14, URL: https://www.irct.ir/trial/56337 .

Indexed as

Carbon DioxideCicatrixHumansIranLasersStromal Vascular FractionCarbon DioxideAblative laserBurn scarCO2 fractional laserCO2 laserEfficacyFractionalLaserSafetySatisfactionScarStromal vascular fractionSVFTrial

Identifiers

PMID37742019
PMCPMC10518108
OpenAlexW4386993680

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.